TY - JOUR T1 - Clinical characteristics of juvenile gout and treatment response to febuxostat JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 599 LP - 600 DO - 10.1136/annrheumdis-2021-221762 VL - 81 IS - 4 AU - Shaoling Zheng AU - Pui Y Lee AU - Yukai Huang AU - Weiming Deng AU - Zhixiang Huang AU - Qidang Huang AU - Shuyang Chen AU - Tianwang Li Y1 - 2022/04/01 UR - http://ard.bmj.com/content/81/4/599.abstract N2 - Gout is a common form of inflammatory arthritis caused by hyperuricaemia and deposition of monosodium urate crystals.1 While risk factors and comorbidities associated with gout are well established in adults,2 3 few studies have examined gout in children.4 There is no treatment guideline for juvenile gout and little is known about the efficacy of urate-lowering therapy in children. Here, we describe the clinical characteristics of 111 patients with juvenile gout evaluated in our centre between 2016 and 2020. We also present data on the efficacy of febuxostat treatment in children.Our cohort of patients with juvenile gout (age of onset ≤18 years) consisted of 107 males and 4 females. All patients met the 2015 ACR/EULAR Criteria for gout. The mean age of symptom onset was 15.2 years and the youngest patient was 9 years old (online supplemental table 1). Compared with adult gout cases (n=533) evaluated during the same period, body mass index was comparable between the groups (p=0.097). Hypertension and kidney stones were comorbidities of gout in adults but not children. Patients with juvenile gout were more likely to provide a family history of gout in first-degree or second-degree relatives (online supplemental table 1).Supplementary data [annrheumdis-2021-221762supp001.pdf] The most common site of gout attacks in children was … ER -